Survival and prognostic factors of pulmonary oligometastases treated with stereotactic body radiotherapy

References

• Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13:8–10.
   PubMed Web of Science ®Google Scholar
• Dongen JA, Slooten EA. The surgical treatment of pulmonary metastases. Cancer Treatment Rev. 1978;5:29–48.
   PubMed Web of Science ®Google Scholar
• Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. J Thorac Cardiovasc Surg. 1997;113:37–49.
   PubMed Web of Science ®Google Scholar
• Ruers T, Punt CJA, van Coevorden F, et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol. 2015;33:3501.
   Web of Science ®Google Scholar
• Gomez DR, Blumenschein GR, Jr Lee JJ, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–1682.
   PubMed Web of Science ®Google Scholar
• Simmonds PC, Primrose JN, Colquitt JL, et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006;94:982–999.
   PubMed Web of Science ®Google Scholar
• Casiraghi M, De Pas T, Maisonneuve P, et al. A 10-year single-center experience on 708 lung metastasectomies: the evidence of the international registry of lung metastases. J Thorac Oncol. 2011;6:1373–1378.
   PubMed Web of Science ®Google Scholar
• Tanvetyanon T, Robinson LA, Schell MJ, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. Jco. 2008;26:1142–1147.
   PubMed Web of Science ®Google Scholar
• Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases a systematic review. J Thorac Oncol. 2010;5:1091–1099.
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, Voort van Zyp CMG, Verhoef C, et al. Stereotactic body radiation therapy for oligometastases to the lung: a phase 2 study. Int J Radiat Oncol Biol Phys. 2015;91:337–343.
   PubMed Web of Science ®Google Scholar
• Hof H, Hoess A, Oetzel D, et al. Stereotactic single-dose radiotherapy of lung metastases. Strahlenther Onkol. 2007;183:673–678.
   PubMed Web of Science ®Google Scholar
• Fode MM, Høyer M. Survival and prognostic factors in 321 patients treated with stereotactic body radiotherapy for oligo-metastases. Radiother Oncol. 2015;114:155–160.
   PubMed Web of Science ®Google Scholar
• Norihisa Y, Nagata Y, Takayama K, et al. Stereotactic body radiotherapy for oligometastatic lung tumors. Int J Radiat Oncol Biol Phys. 2008;72:398–403.
   PubMed Web of Science ®Google Scholar
• Rusthoven KE, Kavanagh BD, Burri SH, et al. Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. Jco. 2009;27:1579–1584.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiao JP, Zhang HZ, et al. Stereotactic body radiation therapy favors long-term overall survival in patients with lung metastases: five-year experience of a single-institution. Chin Med J. 2011;124:4132–4137.
   PubMed Web of Science ®Google Scholar
• Ricardi U, Filippi AR, Guarneri A, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012;75:77–81.
   PubMed Web of Science ®Google Scholar
• Oh D, Ahn YC, Seo JM, et al. Potentially curative stereotactic body radiation therapy (SBRT) for single or oligometastasis to the lung. Acta Oncol. 2012;51:596–602.
   PubMed Web of Science ®Google Scholar
• Navarria P, Ascolese M, Tomatis S, et al. Stereotactic body radiotherapy (sbrt). in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9:91.
   PubMed Web of Science ®Google Scholar
• Aoki M, Hatayama Y, Kawaguchi H, et al. Stereotactic body radiotherapy for lung metastases as oligo-recurrence: a single institutional study. J Radiat Res. 2016;57:55–61.
   PubMed Web of Science ®Google Scholar
• Rieber J, Streblow J, Uhlmann L, et al. Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases—a pooled analysis of the German working group “stereotactic radiotherapy”. Lung Cancer.2016;97:51–58.
   PubMed Web of Science ®Google Scholar
• Sharma A, Duijm M, Oomen-de H, et al. Factors affecting local control for pulmonary oligometastasis treated with stereotactic body radiotherapy. Acta Oncol. 2018;57:1031–1037.
   PubMed Web of Science ®Google Scholar
• Van der Voort Van Zyp NC, Prévost JB, Hoogeman MS, et al. Stereotactic radiotherapy with real-time tumor tracking for non-small cell lung cancer: clinical outcome. Radiother Oncol. 2009;91:296–300.
   PubMed Web of Science ®Google Scholar
• Nuyttens JJ, van de Pol M. The CyberKnife radiosurgery system for lung cancer. Expert Rev Med Devices. 2012;9:465–475.
   PubMed Web of Science ®Google Scholar
• Hoogeman M, Prevost JB, Nuyttens J, et al. Clinical accuracy of the respiratory tumor tracking system of the cyberknife: assessment by analysis of log files. Int J Radiat Oncol Biol Phys. 2009;74:297–303.
   PubMed Web of Science ®Google Scholar
• van der Voort van Zyp NC, Hoogeman MS, van de Water S, et al. Clinical introduction of Monte Carlo treatment planning: a different prescription dose for non-small cell lung cancer according to tumor location and size. Radiother Oncol. 2010;96:55–60.
   PubMed Web of Science ®Google Scholar
• Wilcox EE, Daskalov GM, Lincoln H, et al. Comparison of planned dose distributions calculated by Monte Carlo and Ray-Tracing algorithms for the treatment of lung tumors with cyberknife: a preliminary study in 33 patients. Int J Radiat Oncol Biol Phys. 2010; 77:277–284.
   PubMed Web of Science ®Google Scholar
• Tanadini-Lang S, Rieber J, Filippi AR, et al. Nomogram based overall survival prediction in stereotactic body radiotherapy for oligo-metastatic lung disease. Radiother Oncol. 2017;123:182–188.
   PubMed Web of Science ®Google Scholar
• De Vin T, Engels B, Gevaert T, et al. Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival. Ann Oncol. 2014;25:467–471.
   PubMed Web of Science ®Google Scholar
• Fleckenstein J, Petroff A, Schäfers H-J, et al. Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer. BMC Cancer. 2016;16:348
   PubMed Web of Science ®Google Scholar
• Jiang L, He J, Shi X, et al. Prognosis of synchronous and metachronous multiple primary lung cancers: systematic review and meta-analysis. Lung Cancer. 2015;87:303–310.
   PubMed Web of Science ®Google Scholar
• Lussier YA, Xing HR, Salama JK, et al. MicroRNA expression characterizes oligometastasis(es). PLoS One. 2011;6:e28650
   PubMed Web of Science ®Google Scholar
• Lussier YA, Khodarev NN, Regan K, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One. 2012;7:e50141
   PubMed Web of Science ®Google Scholar
• Onishi H, Matsumoto Y, Miyakawa A, et al. Japanese multiinstitutional study of stereotactic body radiation therapy for totally 380 patients with lung metastases. Int J Radiat Oncol Biol Phys. 2014;90:S46–S47.
   Web of Science ®Google Scholar
• Takeda A, Kunieda E, Ohashi T, et al. Stereotactic body radiotherapy (SBRT) for oligometastatic lung tumors from colorectal cancer and other primary cancers in comparison with primary lung cancer. Radiother Oncol. 2011;101:255–259.
   PubMed Web of Science ®Google Scholar